Physician profile
Christopher South
NPI 1649392341
$21,186.23
in general payments reported to CMS, 2019-2025
23 companies · $200 in 2025
The $200 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19K · 2020: $171 · 2021: $665 · 2022: $803 · 2023: $290 · 2024: $435 · 2025: $200.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $925.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $924.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $12,344.39 | 2019-2025 | Rinvoq, Linzess, Viberzi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $5,232.19 | 2019-2023 | Xifaxan |
| Allergan, INC. | $1,863.68 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $335.31 | 2019-2023 | Entyvio |
| Janssen Biotech, INC. | $256.30 | 2019-2025 | Tremfya |
| Ironwood Pharmaceuticals, INC | $248.83 | 2019-2024 | |
| Pfizer INC. | $151.05 | 2019-2025 | |
| Covidien LP | $128.54 | 2019 | |
| Phathom Pharmaceuticals, INC. | $124.99 | 2024 | Voquezna |
| Qol Medical, LLC | $107.55 | 2021-2023 | Sucraid |
| Endogastric Solutions, INC | $75.80 | 2019 | |
| Ferring Pharmaceuticals INC. | $66.42 | 2020-2022 | |
| Gilead Sciences, INC. | $48.55 | 2021-2025 | |
| Ucb, INC. | $44.32 | 2019 | |
| Novo Nordisk INC | $35.43 | 2025 | Wegovy |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Romark Laboratories, Lc | $27.95 | 2019 | |
| Dova Pharmaceuticals | $19.88 | 2019 | |
| Nestle Healthcare Nutrition INC. | $15.25 | 2022 | |
| Intercept Pharmaceuticals, INC. | $13.56 | 2024 | |
| Shionogi INC | $13.52 | 2019 | |
| Celgene Corporation | $13.24 | 2023 | Zeposia |
| Lucid Diagnostics INC. | $12.11 | 2022 | |
| Micro-Tech Endoscopy USA, INC. | $7.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher South listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.